Revenue
$55.00M
2023
Growth Rate (y/y)
83%
2023
Funding
$5.10M
2023
Revenue
Sacra estimates that Hone grew revenue 4x in 2021 and 2x in 2022, hitting $50M in annualized revenue at the end of 2023.
Compare to Hims & Hers (NYSE: HIMS) at $906M of annualized revenue, up 56% year-over-year off $99 average monthly order value, Thirty Madison at $300M of revenue in 2022 after merging with the female-focused Nurx, and Ro at $300M of revenue in 2021, up 30% from $230M in 2020.
Product
Hone Health (2020) found product-market fit doing an end-around brick-and-mortar low T clinics, replacing in-person visits with mail-order blood testing and testosterone treatment.
Hone took testosterone’s trashy, late-night-infomercial image and rebranded it as a sleek, scientific supplement for male longevity, aggressively marketing it on Facebook, Instagram, and TikTok as a cure-all for brain fog, low libido, ED, poor sleep, weight gain, and chronic fatigue.
Customers start by purchasing a $45 testing kit which includes a remote consultation with a Hone-employed physician. This kit, which can be easily used at home, collects blood samples to measure eight different hormones critical to men's health. After being sent to one of Hone's labs for analysis, customers do a 30-minute FaceTime with one of Hone's physicians.
For those who qualify for testosterone treatment based on clinical evidence of deficiency, Hone offers personalized treatment plans—options range from testosterone injections to sublingual mouth drops and topical creams. Each treatment plan requires follow-up blood tests and consultations every 90 days for the first year.
Business Model
Hone’s core product is their $129/month subscription membership that includes regular blood tests and physician consults and unlocks the ability for customers to order add-ons, like testosterone injections ($28/month) and anastrozole for estrogen reduction ($22/month).
Hone enjoys structurally high customer lifetime value (CLTV) due to their high AOV of $150+ and strong retention driven by the for-life tendency of TRT treatment—particularly when compared to the 50% yearly churn of companies like Ro and Hims that have seen their core product commoditized by the broad availability of generic Viagra and Cialis.
TRT prescription is an ops-heavy business compared to shipping out ED drugs, from collecting and analyzing blood work to managing a patient’s ongoing dosage week-to-week.
Hone Health's pricing structure is designed to be transparent and straightforward, although it tends to be on the higher end when compared to traditional in-person clinics.
The cost of 12 months of intramuscular testosterone treatment ranges from $1,586 to $4,200 at online clinics, with Hone coming in at around $1884. In-person clinics, on the other hand, charge an average of $1,333 per year without insurance and $134 to $781 with insurance. Hone Health's approach to pricing reflects its positioning as a premium provider in the TRT telehealth space.
TAM Expansion
Into their core membership product, Hone is now selling a range of other male enhancement drugs, from metformin for weight loss to glutathione for anti-aging and vitamin B12 injections.
A potential rollback of the COVID-era D2C prescription rules threatens to disrupt the TRT foundation of their business. Ironically, that regulatory risk is mitigated by the bipartisan bodybuilder-trans coalition fighting to keep testosterone easily accessible—albeit for different reasons—led by Massachusetts senators Elizabeth Warren (D) and Ed Markey (D).
In looking at Hone’s avenues for future product expansion, there are a few key opportunities that would make sense to pursue:
Longevity medications
One of the key areas identified for TAM expansion is the introduction of longevity and energy medications. Hone Health's CEO, Saad Alam, has articulated a vision that extends beyond merely addressing testosterone deficiency. The company is actively exploring the inclusion of longevity medications, which represents a significant opportunity to cater to a growing demographic interested in health span and quality of life improvements. This move aligns with the broader trend of consumers seeking preventive and wellness-enhancing treatments, thereby broadening Hone's market reach.
Women’s health
Another notable area for TAM expansion is the foray into women's health. Although Hone Health initially focused on men's health, particularly TRT, the company has recognized the immense potential and need within women's health. By developing and offering services tailored to women, including hormonal optimization and other health services, Hone can tap into a vast and underserved market. This expansion not only aligns with the company's mission of providing momentum and confidence through health optimization but also significantly increases its potential customer base.
Weight loss
Hone Health's strategic plan also includes expanding into medically assisted weight loss and thyroid management. These areas—most notably GLP1 drugs, a market expected to grow to $71B by 2032—represent substantial market opportunities, given the prevalence of obesity and thyroid disorders. By leveraging its telehealth platform and expertise in hormone optimization, Hone can offer personalized and effective treatment plans for these conditions. This expansion not only diversifies Hone's product offerings but also addresses critical health issues affecting a large segment of the population.
News
DISCLAIMERS
This report is for information purposes only and is not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise constitutes a personal trade recommendation to you.
This research report has been prepared solely by Sacra and should not be considered a product of any person or entity that makes such report available, if any.
Information and opinions presented in the sections of the report were obtained or derived from sources Sacra believes are reliable, but Sacra makes no representation as to their accuracy or completeness. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a determination at its original date of publication by Sacra and are subject to change without notice.
Sacra accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that liability arises under specific statutes or regulations applicable to Sacra. Sacra may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect different assumptions, views and analytical methods of the analysts who prepared them and Sacra is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report.
All rights reserved. All material presented in this report, unless specifically indicated otherwise is under copyright to Sacra. Sacra reserves any and all intellectual property rights in the report. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of Sacra. Any modification, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, or selling any report is strictly prohibited. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of Sacra. Any unauthorized duplication, redistribution or disclosure of this report will result in prosecution.